Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21242674 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
Conditions: Chronic Kidney Disease;   Left Ventricular Hypertrophy
Interventions: Drug: paricalcitol;   Drug: placebo

Indicates status has not been verified in more than two years